Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 15/20 | 0.47 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.41 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1505852 | 0.79 | CYP2C19 (0.49) | KCNN4MAPTKMT2A | |
| SCHEMBL23377453 | 0.78 | SMN1; SMN2 (0.41) | KMT2APTGS1 | |
| SCHEMBL11433215 | 0.77 | KCNN4 (0.47) | KCNN4KCNE1KCNQ1MAPTKMT2A | |
| SCHEMBL812971 | 0.74 | KCNN4 (0.76) | KCNN4KCNE1KCNQ1MAPTKMT2A | |
| Carbamic Acid SCHEMBL1982476 | 0.73 | RAB9A (0.39) | MAPTKMT2APTGS1 | |
| SCHEMBL16424227 | 0.73 | MAPT (0.41) | MAPTKMT2APTGS1 | |
| SCHEMBL17592012 | 0.68 | KCNN4 (0.56) | KCNN4KCNE1KCNQ1MAPTKMT2A | |
| SCHEMBL3526866 | 0.68 | KCNN4 (0.56) | KCNN4KCNE1KCNQ1MAPTKMT2A | |
| SCHEMBL4801886 | 0.65 | KMT2A (0.48) | KCNN4KCNE1KCNQ1MAPTKMT2A | |
| SCHEMBL18782553 | 0.65 | KCNN4 (0.72) | KCNN4KCNE1KCNQ1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211916-B2 | Central nervous system disorders; drug abuse; Parkinson's disease; antidepressants | WAYNE STATE UNIVERSITY (US) | 2012-07-03 | — | — | US | disclosed |
| EP-2291378-A2 | N- AND O-SUBSTITUTED 4-Ý2-(DIPHENYLMETHOXY)-ETHYL¨-1-Ý(PHENYL)METHYL¨PIPERIDINE ANALOGS AND METHODS OF TREATING CNS DISORDERS THEREWITH | WAYNE STATE UNIVERSITY (US) | 2011-03-09 | — | — | EP | disclosed |
| US-20100016600-A1 | N- and O-Substituted 4-[2-(Diphenylmethoxy)-Ethyl]-1-[(Phenyl)Methyl]Piperdine Analogs and Methods of Treating CNS Disorders Therewith | WAYNE STATE UNIVERSITY (US) | 2010-01-21 | — | — | US | disclosed |
| US-7595331-B2 | N-and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating CNS disorders therewith | WAYNE STATE UNIVERSITY (US) | 2009-09-29 | — | — | US | disclosed |
| WO-2009094428-A2 | N- AND O-SUBSTITUTED 4-[2-(DIPHENYLMETHOXY)-ETHYL]-1-[(PHENYL)METHYL]PIPERIDINE ANALOGS AND METHODS OF TREATING CNS DISORDERS THEREWITH | WAYNE STATE UNIVERSITY (US) | 2009-07-30 | — | — | WO | disclosed |
| US-20080182991-A1 | N- AND O-SUBSTITUED 4-[2-(DIPHENYLMETHOXY)-ETHYL]-1-[(PHENYL)METHYL]PIPERIDINE ANALOGS AND METHODS OF TREATING CNS DISORDERS THEREWITH | WAYNE STATE UNIVERSITY (US) | 2008-07-31 | — | — | US | disclosed |
| US-6995268-B2 | N- and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1- (phenyl) methyl) piperidine analogs and methods of treating CNS disorders therewith | WAYNE STATE UNIVERSITY (US) | 2006-02-07 | — | — | US | disclosed |
| US-20050154021-A1 | N-and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating CNS disorders therewith | WAYNE STATE UNIVERSITY (US) | 2005-07-14 | — | — | US | disclosed |
| US-20030225133-A1 | N-and o-substituted 4-[2-( diphenylmethoxy) -ethyl]-1- (phenyl) methyl) piperidine analogs and methods of treating cns disorders therewith | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016600-A1 | N- and O-Substituted 4-[2-(Diphenylmethoxy)-Ethyl]-1-[(Phenyl)Methyl]Piperdine Analogs and Methods of Treating CNS Disorders Therewith | SLC6A3, SLC6A2, PNMT | KCNN4 601/4885KCNE1 2082/4885KCNQ1 1249/4885 |
| US-20080182991-A1 | N- AND O-SUBSTITUED 4-[2-(DIPHENYLMETHOXY)-ETHYL]-1-[(PHENYL)METHYL]PIPERIDINE ANALOGS AND METHODS OF TREATING CNS DISORDERS THEREWITH | SLC6A3, SLC6A2, PNMT | KCNN4 601/4885KCNE1 1603/4885KCNQ1 1100/4885 |
| US-20030225133-A1 | N-and o-substituted 4-[2-( diphenylmethoxy) -ethyl]-1- (phenyl) methyl) piperidine analogs and methods of treating cns disorders therewith | SLC6A3, SLC6A2, PNMT | KCNN4 811/4885KCNE1 1745/4885KCNQ1 1316/4885 |
| US-20050154021-A1 | N-and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating CNS disorders therewith | SLC6A3, SLC6A2, PNMT | KCNN4 614/4885KCNE1 1897/4885KCNQ1 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.